Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion

• Published in: British journal of cancer 1997-05, Vol.75 (10), p.1497-1500
• Main Authors: Kuppen, PJK, Jonges, LE, van de Velde, CJH, Vahrmeijer, AL, Tollenaar, RAME, Borel Rinkes, IHM, Eggermont, AMM
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Biopsy; Cancer Research; clinical-oncology; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - pathology; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Drug Resistance; Enzyme-Linked Immunosorbent Assay; Epidemiology; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver - metabolism; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Liver Neoplasms - secondary; Male; Medical sciences; Melphalan - administration & dosage; Middle Aged; Molecular Medicine; Oncology; Perfusion; Pharmacology. Drug treatments; Tumor Necrosis Factor-alpha - administration & dosage; Tumor Necrosis Factor-alpha - metabolism
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1997.255

In this study we determined the level of tumour necrosis factor alpha (TNF-alpha) in liver and tumour tissue samples obtained from patients with colorectal metastases confined to the liver, who were treated with isolated liver perfusion with TNF-alpha and melphalan. We adapted a standard enzyme-linked immunosorbent assay kit for the quantification of TNF-alpha in serum to measure the amount of this cytokine in solid tissue. For this purpose, we developed a buffer that lysed the tissues without affecting the TNF-alpha present. The minimum detection level was about 2 pg of TNF-alpha per mg tissue. Using this technique, we found a significant increase in the TNF-alpha level after perfusion in the liver tissue of all evaluable patients, which may explain the transient liver toxicity we observed in all patients. In tumour tissue, a significant TNF-alpha increase was observed in one out of five patients. The level of TNF-alpha in all liver tissue samples and some of the tumours after treatment by isolated liver perfusion was much higher than the peak serum concentrations obtained after systemic administration of the maximum tolerated dose of TNF-alpha. Furthermore, we demonstrated that the level of TNF-alpha in the liver tissue samples was about seven to eight times higher than in tumour tissue. We concluded that regional liver treatment resulted in a relatively high local level of TNF-alpha, but also that this cytokine did not preferentially accumulate in tumour tissue.